PUBLIC COMPANY
saveSERVIER
USupdated 3mo ago
community read0 votes
pipeline
0
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(0)
no pipeline products on record
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
🐶 Hiring Signal
News
- Pfizer CFO to depart; GSK wins approval for UTI drugPlus news about Apellis Pharmaceuticals, Servier, TORL BioTherapeutics, Verastem, Corcept Therapeutics, Legend Biotech, COUR Pharmaceuticals, cAMPfield Therapeutics and LabGenius Therapeutics. 👋 P…endpoints · 1mo ago
- Shattuck raises $75M; Servier inks neuro ASO pact with n-Lorem FoundationShattuck Labs initiates $75M public offering: The US biotech {$STTK} is selling over 10.5 million shares for $4 apiece, and issuing pre-funded warrants for certain investors. The offering is set to…endpoints · 1mo ago
- STAT+: Longevity startup NewLimit raises $435 million ahead of first clinical trialLongevity startup NewLimit plans to launch its first clinical trial of a liver medicine after raising a staggering $435 million in new funding.stat · 2mo ago
- STAT+: Radiopharmaceutical shows promise in post-Pluvicto settingAbivax's ulcerative colitis data, Fulcrum's scrapped sickle cell drug, and more biotech news from The Readoutstat · 2mo ago
- STAT+: Abivax ulcerative colitis drug shows strong efficacy, but cases of cancer raise concernsAbivax said its experimental treatment for ulcerative colitis showed significant efficacy in a closely watched trial, but shares of the company tanked on safety concerns.stat · 2mo ago
- STAT+: At ASCO, talk of barriers to cancer care, new treatments, and other big takeawaysHere is some of what you may have missed from the world's largest cancer research meeting.stat · 2mo ago
- Servier buys into muscular dystrophy with potentially $2.7B dealThe French drugmaker has agreed to acquire an experimental tablet from Edgewise Therapeutics that some bullish analysts say could eventually hit peak sales of over $2 billion.biopharma_dive · 2mo ago
- STAT+: A turning point for pancreatic cancer patientsEli Lilly announces two China deals, Akeso's lung cancer bispecific payoff, and more biotech news from The Readoutstat · 2mo ago
- Servier signs $1.55B upfront deal for Edgewise's muscular dystrophy assetsServier will pick up the muscular dystrophy business from Edgewise Therapeutics for $1.55 billion upfront, giving the French pharma company access to an experimental neuromuscular medicine that cou…endpoints · 2mo ago
- STAT+: Servier to buy Edgewise Therapeutics’ muscular dystrophy drugThe French pharma firm Servier is buying an experimental muscular dystrophy drug from Edgewise Therapeutics for $1.55 billion upfront.stat · 2mo ago
comments(0)
5-min edit window · permanent after that